CALGARY, Alberta – Zenith Epigenetic Ltd. (“Zenith” or the “Company”) today held its annual general meeting of shareholders (“AGM”), during which President & CEO Donald McCaffrey provided an update to investors on ZEN-3694’s clinical development program for the treatment of NUT carcinoma. Highlights from the presentation are summarized below and...

CHANHASSEN, Minn. — Alpheus Medical, Inc., a private, clinical-stage biotechnology company, today announced the initiation of its Phase 2b randomized controlled trial in newly diagnosed glioblastoma (nGBM) with 10 patients enrolled to date and additional clinical sites continuing to come online. Glioblastoma is a highly infiltrative brain tumor in which cancer cells...

HOUSTON, Texas — Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. David Beers and Dr. Stanley Appel at the Houston Methodist Neurological Institute. The study included the longitudinal measurement...